Professor Uccelli has managed to win a large number of funding, both nationally and internationally, providing more than € 2,500,000.00 to study and research methodologies aimed to seeking a possible cure for multiple sclerosis, so creating occupation both at laboratory and administrative level. For brevity, only those of the last 6 years are reported.

• International Grants (last 6 years)
• National Grants (last 6 years)

2016:

• ERA-NET – Call EraCoSysMed – “Personalizing health care in Multiple Sclerosis using systems medicine tools – Sys4MS”. (€165.000,00)
• Motor Neuron Disease Association (UK) - “Exosome-shuttled miRNAs as mediators of the therapeutic effect of mesenchymal stem cells in ALS” (200.000,00£)

2015:

• Paul Allen Family Foundation (USA) “Can Mesenchymal Stem Cell Secretome Repair Alzheimer’s Disease Brains?” (€100.000,00)
• Grant for Multiple Sclerosis Innovation (GMSI) Project: “Driving microglia metabolism toward remyelination and restoration of brain damage in multiple sclerosis”. (€350,000,00)

2013:

• Biogen USA, “Dissection of the role of HCAR2 in the therapeutic features and potential side effects exerted by dimethylfumarate in multiple sclerosis”. (€247.000,00)

2012:

• Fondazione ARSEP: “A French-Italian collaboration for the MESEMS (MEsenchymal StEm cells for the therapy of Multiple Sclerosis) trial” (€175.000,00)

Top

2017:

• Biogen – “Effects of daclizumab on NK cell-T cell interactions and ILC homeostasis in multiple sclerosis” (€213,000.00)
• Merck KGaA – “Dissection of the distinct susceptibility of hematopoietic precursors and immune cells to cladribine” (€126.500,00)

2016:

• Compagnia di San Paolo, “Studio dell’effetto immunomodulante e neuroriparativo delle cellule staminali mesenchimali in pazienti con sclerosi multipla” (€137.000,00)

2015:

• Novartis Italia, “Assessment of the effect of fingolimod on new pathways involved in neuroprotection” (€101,900,00)
• Italian Foundation For Multiple Sclerosis (FISM), “Targeting terapeutico dell'attività e dell'espressione di REST allo scopo di ridurre la neurodegenrazione ed i deficit sinaptici in modelli di EAE cronica” PI (€235.000,00)
• Fondazione Cariplo “Aged induced hematopoietic and neurogenic dysfunctions contribute to the worse outcome” Co-PI (€100.000,00)

2014:

• Merck Serono Italia, “Effect of Interferon (IFN)-β on Mesenchymal Stem Cells “(€50.000,00)

2012:

• Fondazione CARIGE finanziamento per il progetto: ”Studio clinico sull'uso delle cellule staminali mesenchimali per la cura della Sclerosi Multipla (studio MESEMS)” (€ 125.000,00)
• Novartis Pharma: Studio di un modello murino transgenico per la caratterizzazione del proteoglicano NG2/CSPG4 nella patogenesi della sclerosi multipla. (€ 45.000,00)

2011:

• ITALIAN MINISTRY OF HEALTH “Preclinical evaluation of the NAMPT inhibitor FK866 for the treatment of autoimmunity and lymphoblastic leukemia” Co-PI (€ 631.111,00)
• Merck Serono “Charaterization of the effects of cladibrine on adaptive immune responses in mice and humans” (€ 240.000,00)
• Italian Foundation For Multiple Sclerosis (FISM), 2011-2015: “Progetto Speciale 2011-2014: Cellule Staminali mesenchimali per la terapia della SM”. PI (€ 900.000,00)
• ITALIAN MINISTRY OF UNIVERSITY AND RESEARCH – PRIN 2009 “Identificazione di nuove sorgenti di cellule staminali per la cura della sclerosi multipla” (€ 278.454,00)
• Italian Foundation for Multiple Sclerosis (FISM): Exploitation of a transgenic mouse model for the unveiling of the role of proteoglycan NG2/CSPG4 in the pathogenesis of multiple sclerosis (€ 30.000,00)

Top